BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11163669)

  • 1. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
    McCluskie MJ; Davis HL
    J Immunol; 1998 Nov; 161(9):4463-6. PubMed ID: 9794366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.
    Wu HY; Russell MW
    Vaccine; 1998; 16(2-3):286-92. PubMed ID: 9607044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Wallerström G; Holmgren J
    Vaccine; 2001 May; 19(25-26):3360-8. PubMed ID: 11348699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Miura Y; Matano K; Goto N; Tochikubo K
    Vaccine; 1999 Feb; 17(7-8):944-8. PubMed ID: 10067701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin.
    Tochikubo K; Isaka M; Yasuda Y; Kozuka S; Matano K; Miura Y; Taniguchi T
    Vaccine; 1998; 16(2-3):150-5. PubMed ID: 9607023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit.
    Takahashi Y; Kumada H; Hamada N; Haishima Y; Ozono S; Isaka M; Yasuda Y; Tochikubo K; Umemoto T
    Oral Microbiol Immunol; 2007 Dec; 22(6):374-80. PubMed ID: 17949339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.
    Blanchard TG; Lycke N; Czinn SJ; Nedrud JG
    Immunology; 1998 May; 94(1):22-7. PubMed ID: 9708182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
    Maeyama J; Isaka M; Yasuda Y; Matano K; Kozuka S; Taniguchi T; Ohkuma K; Tochikubo K; Goto N
    Microbiol Immunol; 2001; 45(2):111-7. PubMed ID: 11293476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant.
    Goto N; Maeyama J; Yasuda Y; Isaka M; Matano K; Kozuka S; Taniguchi T; Miura Y; Ohkuma K; Tochikubo K
    Vaccine; 2000 Apr; 18(20):2164-71. PubMed ID: 10715532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L; Filler M; Sjöholm I
    Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.